Journal of Critical Care
Volume 23, Issue 1 , Pages 64-73, March 2008

Correlates of clinical failure in ventilator-associated pneumonia: insights from a large, randomized trial

  • Andrew F. Shorr, MD

      Affiliations

    • Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC, USA
  • ,
  • Deborah Cook, MD

      Affiliations

    • Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    • Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
  • ,
  • Xuran Jiang, MSc

      Affiliations

    • Clinical Evaluation Research Unit, Kingston General Hospital, Kingston, Ontario, Canada
  • ,
  • John Muscedere, MD

      Affiliations

    • Clinical Evaluation Research Unit, Kingston General Hospital, Kingston, Ontario, Canada
    • Department of Medicine, Queen's University, Kingston, Ontario, Canada
  • ,
  • Daren Heyland, MD, MSc

      Affiliations

    • Clinical Evaluation Research Unit, Kingston General Hospital, Kingston, Ontario, Canada
    • Department of Medicine, Queen's University, Kingston, Ontario, Canada
    • Corresponding Author InformationCorresponding author. Tel.: +1 613 549 6666x3339; fax: +1 613 548 1351.
  • ,
  • for the Canadian Critical Care Trials Group

Abstract 

Purpose

Our objective was to determine clinical variables measured at baseline and day 3 that may relate to failure of resolution of ventilator-associated pneumonia (VAP).

Materials and Methods

In patients with confirmed VAP derived from a large, randomized controlled trial comparing different modalities for the diagnosis and treatment of VAP, we identified risk factors associated with clinical failure. Clinical failure was prospectively defined in this trial as death, persistence of clinical and radiographic features of infection throughout the study period requiring additional antibiotics, superinfection, or relapsing infection. We examined the relationship between VAP resolution and clinical characteristics measured both at study enrollment and at day 3. We used logistic regression to identify independent factors associated with clinical failure and conducted a sensitivity analysis focusing only on patients who met the definition for clinical failure but who nonetheless survived until day 28.

Results

Of 563 subjects with VAP, 179 (31.8%) were classified as clinical failures. Death was the most common reason for clinical failure. At baseline, clinical failure patients were older, more severely ill, had been on mechanical ventilation for a longer period, and had higher Clinical Pulmonary Infection Score values and lower Pao2/Fio2 ratios. By day 3, patients defined as clinical failures remained more severely ill and continued to have worse oxygenation. In multivariate analysis, 4 factors were independently associated with clinical failure: older age, duration of ventilation before enrollment, presence of neurologic disease at admission, and failure of the Pao2/Fio2 ratio to improve by day 3. Repeating this multivariable model in only surviving patients suggested that persistence of fever was the only variable associated with clinical failure.

Conclusions

Clinical characteristics correlate with eventual outcomes in VAP. Failure of the Pao2/Fio2 ratio and fever to improve are independently associated with clinical failure. We suggest that clinicians follow these measures and consider integrating them in their decisions as to when to reevaluate persons with VAP who are not improving.

Keywords: Failure, Pneumonia, Resolution, Ventilator-associated pneumonia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by grants from the Canadian Institutes of Health Research and Physicians' Services Incorporated of Ontario, and by unrestricted grants from AstraZeneca and Bayer.

PII: S0883-9441(07)00200-6

doi:10.1016/j.jcrc.2007.11.010

Journal of Critical Care
Volume 23, Issue 1 , Pages 64-73, March 2008